Computational repurposing of approved drugs targeting KRAS G12D and EGFR for colorectal cancer therapy | Synapse
March 3, 2026Open Access
Computational repurposing of approved drugs targeting KRAS G12D and EGFR for colorectal cancer therapy
Key Points
Carteolol may serve as a promising dual-targeting therapeutic agent for colorectal cancer.
In silico predictions indicate its ability to target both KRAS G12D and EGFR mutations.
Computational repurposing methods analyze existing drugs for effective cancer treatment options.
Further biochemical and cellular validation is essential to confirm its clinical relevance.
Abstract
This in silico study predicts Carteolol as a potential dual-targeting therapeutic agent, requiring biochemical and cellular validation before clinical relevance can be established.